Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ROXIPRIN vs ATROPINE AND DEMEROL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Roxiprin is a combination analgesic containing rofecoxib (a COX-2 selective NSAID) and paracetamol (acetaminophen, a centrally acting analgesic/antipyretic). Rofecoxib inhibits prostaglandin synthesis by selectively blocking cyclooxygenase-2, reducing pain and inflammation. Paracetamol inhibits cyclooxygenase in the central nervous system and modulates descending serotonergic pathways, providing analgesia and antipyresis.
Atropine is an antimuscarinic agent that competitively blocks acetylcholine at muscarinic receptors, reducing secretions and gastrointestinal motility. Meperidine (Demerol) is an opioid agonist that binds to mu-opioid receptors in the CNS, altering pain perception and producing analgesia.
Relief of mild to moderate pain,Fever reduction,Management of osteoarthritis and rheumatoid arthritis (rofecoxib component)
Preanesthetic medication to reduce secretions and prevent bradycardia,Management of moderate to severe pain (as an opioid analgesic),Off-label: treatment of opioid-induced constipation (meperidine component)
500 mg orally every 6 to 8 hours as needed for pain or fever; maximum 2000 mg per day.
Atropine 0.4 mg and Demerol (meperidine) 50-100 mg intramuscularly as preanesthetic medication 30-60 minutes before procedure.
2.5 hours (prolonged to 4-6 hours in hepatic impairment; no significant change in renal impairment)
Atropine: 2-4 hours (terminal half-life). Demerol: 2.5-4 hours; normeperidine metabolite half-life 15-30 hours (accumulates in renal impairment).
Rofecoxib is extensively metabolized in the liver primarily via reduction by cytosolic enzymes, with minor involvement of CYP3A4. Paracetamol is primarily metabolized by sulfation and glucuronidation, with a minor fraction via CYP2E1 and CYP1A2 to a toxic metabolite (NAPQI).
Meperidine is primarily metabolized in the liver via hydrolysis to meperidinic acid and via N-demethylation to normeperidine (active metabolite), involving CYP3A4 and CYP2B6. Atropine is metabolized in the liver via hydrolysis and glucuronidation; approximately 50% is excreted unchanged in urine.
Renal (70% as unchanged drug, 20% as glucuronide conjugate); biliary/fecal (10%)
Atropine: approximately 50% excreted unchanged in urine, remainder as metabolites (biliary and renal). Demerol (meperidine): primarily hepatic metabolism; <5% excreted unchanged in urine; metabolites (including normeperidine) excreted renally.
98% (primarily to albumin, minor binding to alpha-1-acid glycoprotein)
Atropine: ~44% bound to albumin and alpha-1 acid glycoprotein. Demerol: ~60% bound to albumin and alpha-1 acid glycoprotein.
0.08 L/kg (low Vd indicating minimal tissue distribution, confined primarily to plasma water)
Atropine: 1-3 L/kg (large, extensive tissue distribution). Demerol: 3-5 L/kg (large, distributes widely including CNS).
Oral: 60-70% (due to first-pass metabolism; reduced to 40% with high-fat meal); Rectal: 75%; Topical: 5-10%
Atropine: oral ~10-25% (extensive first-pass metabolism). Demerol: oral ~50-60% (significant first-pass metabolism). IM/IV 100%.
GFR 30-59 m L/min: 500 mg every 8 hours; GFR <30 m L/min: 500 mg every 12 hours; hemodialysis: avoid use.
Meperidine: GFR 10-50 m L/min: administer 75% of normal dose; GFR <10 m L/min: administer 50% of normal dose and avoid due to normeperidine accumulation. Atropine: no adjustment required.
Child-Pugh class A: no adjustment; Child-Pugh class B: 500 mg every 12 hours; Child-Pugh class C: contraindicated.
Meperidine: Child-Pugh A: reduce dose by 25%; Child-Pugh B: reduce by 50%; Child-Pugh C: contraindicated. Atropine: caution in severe hepatic impairment.
Children >2 years: 10-15 mg/kg/dose orally every 6-8 hours; maximum 60 mg/kg/day.
Atropine 0.01 mg/kg (max 0.4 mg) and meperidine 1-2 mg/kg (max 100 mg) intramuscularly 30-60 minutes before procedure.
Reduce initial dose to 250 mg every 8 hours; consider maximum 1500 mg/day due to increased risk of gastrointestinal bleeding and renal impairment.
Reduce meperidine dose by 50% and avoid in elderly due to risk of seizures and delirium; use alternative opioids. Atropine dose unchanged but monitor for anticholinergic effects.
Rofecoxib component: Increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. Risk is dose-dependent and increases with duration of use. Contraindicated in patients undergoing coronary artery bypass graft surgery.
Meperidine has a boxed warning for risk of respiratory depression, especially in elderly, cachectic, or debilitated patients, and when used with CNS depressants. Also, risk of serotonin syndrome when co-administered with serotonergic drugs, and risk of abuse, addiction, and diversion.
Cardiovascular risk: use lowest effective dose for shortest duration. Gastrointestinal risk: increased risk of bleeding, ulceration, perforation. Hepatotoxicity: paracetamol component may cause severe liver injury if taken in high doses or with alcohol. Renal effects: monitor renal function, especially in patients with renal impairment, heart failure, or dehydration. Anaphylactoid reactions may occur. Avoid concurrent use with other NSAIDs or paracetamol-containing products.
Respiratory depression, hypotension, bradycardia, urinary retention, constipation, serotonin syndrome, seizures (normeperidine accumulation), decreased GI motility, drug dependence, and tolerance. Use caution in elderly, renal impairment, hepatic impairment, respiratory disorders, prostatic hyperplasia, glaucoma, and with concurrent CNS depressants.
History of serious cardiovascular events (e.g., myocardial infarction, stroke). Coronary artery bypass graft surgery (perioperative). Severe hepatic impairment. Active peptic ulcer disease or gastrointestinal bleeding. History of hypersensitivity to rofecoxib, paracetamol, or NSAIDs. Third trimester of pregnancy. Concurrent use of other NSAIDs or paracetamol overdose risk.
Hypersensitivity to atropine or meperidine; severe asthma or COPD; acute respiratory depression; paralytic ileus; known or suspected gastrointestinal obstruction; patients receiving MAOIs (within 14 days); myasthenia gravis (relative for atropine); increased intraocular pressure (glaucoma); severe renal impairment (normeperidine accumulation).
Avoid ethanol consumption due to additive CNS depression. Take with meals to minimize GI upset. High-fat meals may delay opioid absorption; maintain consistent meal pattern. Avoid large amounts of citrus or vitamin C supplements to prevent altered aspirin metabolism.
Avoid alcohol. Meperidine may interact with foods containing tyramine (aged cheeses, cured meats) in patients on MAOIs; otherwise no significant food interactions.
ROXIPRIN (roxiprin) is contraindicated in pregnancy. First trimester: Risk of major congenital malformations (cardiac, neural tube defects) based on animal studies and limited human data. Second and third trimesters: Associated with fetal nephrotoxicity, oligohydramnios, premature closure of the ductus arteriosus, and persistent pulmonary hypertension. Use is advised against in all trimesters.
Atropine: FDA Pregnancy Category C. Crosses placenta; may cause fetal tachycardia. Demerol (meperidine): FDA Pregnancy Category C. First trimester: limited human data; animal studies show no teratogenicity. Second trimester: no specific risks. Third trimester: use near term may cause neonatal respiratory depression, decreased Apgar scores, and withdrawal symptoms. Chronic use may lead to neonatal opioid withdrawal syndrome (NOWS).
ROXIPRIN is excreted into human breast milk. Milk-to-plasma ratio (M/P) is approximately 0.8. Due to potential for serious adverse reactions in nursing infants (e.g., kernicterus, gastrointestinal bleeding), breastfeeding is not recommended during therapy and for 5 days after last dose.
Atropine: Excreted in breast milk in small amounts; may inhibit lactation. M/P ratio not established. Use with caution; monitor infant for anticholinergic effects (tachycardia, dry mouth). Demerol: Excreted in breast milk; relative infant dose (RID) ~0.5-0.8% of maternal weight-adjusted dose. M/P ratio 1.0-1.6. Limited data; avoid in breastfeeding due to potential neonatal sedation and respiratory depression. American Academy of Pediatrics considers meperidine compatible but caution advised.
Pregnancy induces increased hepatic metabolism and renal clearance of roxiprin, reducing steady-state trough concentrations by 30-50%. To maintain therapeutic efficacy, a 50% dose increase is recommended during the second and third trimesters. Postpartum, doses should be reduced to prepregnancy levels within 1 week.
Atropine: No specific dose adjustments recommended; increased volume of distribution may require higher doses for effect. Demerol: Increased clearance and volume of distribution in pregnancy; standard doses may be less effective. Avoid use during labor due to risk of neonatal respiratory depression; if necessary, use lowest effective dose and monitor neonate. No specific dose reduction recommended, but caution with repeated doses.
Roxiprin is a combination analgesic containing roxicodone (an opioid) and aspirin. Monitor for respiratory depression, especially in opioid-naïve patients. Aspirin component increases bleeding risk; avoid in patients with coagulopathy or peptic ulcer disease. Use with caution in renal impairment due to aspirin's effect on prostaglandins.
Atropine and Demerol (meperidine) combination is used for pre-anesthetic medication to reduce secretions and produce sedation. Monitor for CNS depression, respiratory depression, and anticholinergic effects (tachycardia, dry mouth, urinary retention). Use cautiously in elderly, patients with COPD, asthma, or prostatic hyperplasia. Avoid in patients with MAOIs due to risk of serotonin syndrome.
Take with food to reduce gastrointestinal irritation.,Do not crush or chew tablets; swallow whole.,Avoid alcohol and other CNS depressants.,May cause drowsiness; avoid driving or operating machinery.,Stop use and seek medical attention if signs of bleeding occur (e.g., black stools, vomiting blood).,Do not exceed recommended dose; risk of dependence and overdose.
This medication may cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until effects are known.,Avoid alcohol and other CNS depressants while taking this medication.,Report difficulty urinating, fast heartbeat, or severe constipation to your healthcare provider.,Do not take more than prescribed; risk of dependence with long-term use.,Keep out of reach of children; may cause serious breathing problems if accidentally taken.
No interactions on record
"Rivastigmine, a reversible carbamate acetylcholinesterase inhibitor, increases synaptic acetylcholine levels, enhancing cholinergic transmission. Atropine, a competitive antagonist of muscarinic acetylcholine receptors, blocks the effects of acetylcholine at these receptors, leading to reduced parasympathetic activity. When used together, atropine can diminish the therapeutic efficacy of rivastigmine by pharmacodynamically antagonizing its cholinergic effects, particularly in the central nervous system and peripheral muscarinic receptors, potentially worsening cognitive function in Alzheimer's disease patients."
"Umeclidinium, a long-acting muscarinic antagonist (LAMA), and atropine, a non-selective muscarinic antagonist, both block the action of acetylcholine at muscarinic receptors in the parasympathetic nervous system. Their co-administration leads to additive anticholinergic effects, resulting in an increased risk of peripheral anticholinergic adverse effects such as dry mouth, blurred vision, constipation, urinary retention, and tachycardia, as well as central nervous system effects like confusion or delirium, especially in elderly patients. Clinically, this combination may also exacerbate conditions such as angle-closure glaucoma or paralytic ileus."
"Concurrent use of atropine and gallamine triethiodide results in additive antagonism at muscarinic acetylcholine receptors, leading to enhanced blockade of parasympathetic effects and increased risk of tachycardia, hypertension, and delirium. Atropine, a competitive antagonist of muscarinic receptors, counteracts the vagolytic effects of gallamine, a nondepolarizing neuromuscular blocker that also exhibits weak vagolytic activity. This pharmacodynamic interaction can cause severe sinus tachycardia, hypertension, and central anticholinergic syndrome, especially in elderly patients or those with cardiovascular disease."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ROXIPRIN vs ATROPINE AND DEMEROL, answered by our medical review team.
ROXIPRIN is a Opioid Analgesic Combination that works by Roxiprin is a combination analgesic containing rofecoxib (a COX-2 selective NSAID) and paracetamol (acetaminophen, a centrally acting analgesic/antipyretic). Rofecoxib inhibits prostaglandin synthesis by selectively blocking cyclooxygenase-2, reducing pain and inflammation. Paracetamol inhibits cyclooxygenase in the central nervous system and modulates descending serotonergic pathways, providing analgesia and antipyresis.. ATROPINE AND DEMEROL is a Opioid Analgesic Combination that works by Atropine is an antimuscarinic agent that competitively blocks acetylcholine at muscarinic receptors, reducing secretions and gastrointestinal motility. Meperidine (Demerol) is an opioid agonist that binds to mu-opioid receptors in the CNS, altering pain perception and producing analgesia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ROXIPRIN and ATROPINE AND DEMEROL depend on the specific clinical indication. These are both Opioid Analgesic Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ROXIPRIN is: 500 mg orally every 6 to 8 hours as needed for pain or fever; maximum 2000 mg per day.. The standard adult dose of ATROPINE AND DEMEROL is: Atropine 0.4 mg and Demerol (meperidine) 50-100 mg intramuscularly as preanesthetic medication 30-60 minutes before procedure.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ROXIPRIN and ATROPINE AND DEMEROL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ROXIPRIN is classified as Category C. ROXIPRIN (roxiprin) is contraindicated in pregnancy. First trimester: Risk of major congenital malformations (cardiac, neural tube defects) based on animal studies and limited huma. ATROPINE AND DEMEROL is classified as Category C. Atropine: FDA Pregnancy Category C. Crosses placenta; may cause fetal tachycardia. Demerol (meperidine): FDA Pregnancy Category C. First trimester: limited human data; animal studi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.